INVO Fertility (NASDAQ:IVF) Issues Quarterly Earnings Results

INVO Fertility (NASDAQ:IVF) posted its quarterly earnings data on Monday. The company reported ($3.38) EPS for the quarter, FiscalAI reports. The firm had revenue of $2.02 million for the quarter.

INVO Fertility Price Performance

Shares of IVF opened at $1.50 on Monday. INVO Fertility has a 12 month low of $1.26 and a 12 month high of $183.60. The firm’s 50 day moving average is $1.75 and its 200-day moving average is $3.85. The stock has a market capitalization of $2.69 million, a PE ratio of -0.00 and a beta of 2.33. The company has a current ratio of 0.27, a quick ratio of 0.25 and a debt-to-equity ratio of 0.15.

Institutional Investors Weigh In On INVO Fertility

A hedge fund recently bought a new stake in INVO Fertility stock. Armistice Capital LLC acquired a new position in shares of INVO Fertility, Inc (NASDAQ:IVF) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 207,644 shares of the company’s stock, valued at approximately $156,000. Armistice Capital LLC owned 8.69% of INVO Fertility at the end of the most recent reporting period. 12.02% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on IVF shares. Weiss Ratings raised INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Wall Street Zen raised INVO Fertility from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.